Arzerra OverviewOfatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received co...
Read more Arzerra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ofatumumab
Recent Arzerra Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 100mg/5ml
NDC Database Records for Arzerra: (4 results)Sorted by National Drug Code
- 0078-0669 Arzerra 20 mg/ml Intravenous Injection, Solution by Novartis Pharmaceuticals Corporation
- 0078-0690 Arzerra 20 mg/ml Intravenous Injection, Solution by Novartis Pharmaceuticals Corporation
- 0173-0821 Arzerra 20 mg/ml Intravenous Injection, Solution by Glaxosmithkline LLC
- 63379-023 Arzerra 20 mg/ml Intravenous Injection, Solution by Glaxo Operations Uk Ltd